1. Wogonoside has anti-inflammatory, anti-angiogenic and anticancer effects, it may exert its anti-inflammatory effect via dual inhibition of NF-κB and NLRP3 inflammasome.
2. Wogonoside markedly inhibits histamine release in cells stimulated with calcium ionophore A23187 or compound 48/80 and markedly inhibits LTB 4 production at the concentration of 100 uM.
3. Wogonoside inhibits lipopolysaccharide-induced angiogenesis in vitro and in vivo via toll-like receptor 4 signal transduction, and that it might have a therapeutic potential for the diseases associated with the development of both inflammation and progress.
4. Wogonoside induces cell cycle arrest and differentiation by affecting expression and subcellular localization of PLSCR1 in acute myeloid leukemia (AML) cells, it may represent a therapeutic candidate for the treatment of AML.
5. Wogonoside partially inhibits MDA-MB-231 cell growth by inducing autophagy through the MAPK-mTOR pathway and may be a promising anti-tumor agent.
6. Wogonoside inhibits thrombin-catalyzed fibrin polymerization and platelet aggregation, it also elicits anticoagulant effects in mice, it possesses antithrombotic activities and offers a basis for development of a novel anticoagulant.
7. Wogonoside exhibits a protective effect on LPS-induced acute lung injury (ALI) via suppression of TLR4-mediated NF-κB signaling pathways.
1. Corchoionoside C has antioxidant activity, shows strong scavenging activities on DPPH radical.
2. Corchoionosides A, B, and C inhibit the histamine release from rat peritoneal exudate cells induced by antigen-antibody reaction.
3. Corchoionoside C shows weak antifungal activity.
1. Zeorin shows antimycobacterial activity.
2. Zeorin shows strong activity against bacteria and fungi.
1. Confluentin has antimicrobial activity against the gram-positive bacteria.
2. Confluentin significantly inhibits compound 48/80-induced histamine release from rat peritoneal mast cells.
3. Confluentin shows weak cytotoxicity against four human tumor cell lines, HL-60, SMMC-7712, A-549, and MCF-7, in vitro.
1. Taxiresinol shows notable anticancer activity in the in vitro bioassays against colon, liver, ovarian and breast cancer cell lines.
2. Taxiresinol and (7' R)-7'-hydroxylariciresinol can protect the hepatocytes from apoptosis via an inhibition of TNF- alpha production by activated macrophages and a direct inhibition of apoptosis induced by TNF- alpha in D-GalN/LPS-treated mice.
3. Taxiresinol possesses significant antinociceptive activity against p -benzoquinone-induced abdominal contractions.
4. Taxiresinol shows anti-inflammatory activity, it can significantly inhibit carrageenan-induced hind paw edema in mice.
5. Taxiresinol has antiallergic activity, it show inhibitory activity on induced histamine release from the human basophilic cell line, KU812.